Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683020 | 1.00 | PGR (0.50) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL627946 | 0.98 | PGR (0.49) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL901698 | 0.98 | PGR (0.49) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL30337118 | 0.88 | PGR (0.50) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL14816808 | 0.86 | PGR (0.49) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL890238 | 0.86 | PGR (0.49) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL15898256 | 0.85 | TRPM8 (0.55) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL13179256 | 0.85 | PGR (0.47) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL18117369 | 0.85 | PGR (0.47) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL11494728 | 0.85 | NR1H2 (0.43) | NR1H2NR1H3CYP2D6SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10787441-B2 | Hepatitis C virus inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10738062-B2 | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190185486-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2990406-B1 | BENZIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING BENZIDINE DERIVATIVE FOR TREATING LIVER DISEASE CAUSED BY HEPATITIS C VIRUS | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2018-12-26 | — | — | EP | disclosed |
| WO-2008144380-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787441-B2 | Hepatitis C virus inhibitors | HAVCR2, FABP1, SLC10A1 | PGR 1784/4885ADRA2A 3956/4885ADRA2B 3659/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PGR 2200/4885ADRA2A 4127/4885ADRA2B 3726/4885 |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | HAVCR2, HCCS, ZC3HAV1 | PGR 1547/4885ADRA2A 1381/4885ADRA2B 1717/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PGR 4048/4885ADRA2A 4679/4885ADRA2B 4738/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PGR 2200/4885ADRA2A 4127/4885ADRA2B 3726/4885 |
| US-10738062-B2 | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | HAVCR2, C3AR1, HCCS | PGR 544/4885ADRA2A 400/4885ADRA2B 932/4885 |
| US-20190185486-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, C3AR1, HCCS | PGR 544/4885ADRA2A 400/4885ADRA2B 932/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PGR 4048/4885ADRA2A 4679/4885ADRA2B 4738/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PGR 2200/4885ADRA2A 4127/4885ADRA2B 3726/4885 |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, FABP1, SLC10A1 | PGR 1784/4885ADRA2A 3956/4885ADRA2B 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.